Cipla reports FY25 PAT higher 28.4% at Rs. 5,273 Cr

The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore

Akums appoints Shantanu R Chobhe as Corporate Quality Assurance Head

Chobhe brings over 30 years of extensive experience in quality and regulatory management within the pharmaceutical industry

Cipla gets 6 observations from USFDA for Goa facility

The company will work closely with the USFDA and is committed to address these comprehensively within stipulated time

Cipla receives 1 observation from USFDA for Kurkumbh facility

The company is committed to address this observation comprehensively within stipulated time

USFDA conducts inspection at InvaGen manufacturing facility in Central Islip, NY, USA

InvaGen has received 5 inspectional observations in Form 483

Supriya Lifescience Limited appoints of Dr. Shekhar Bhirud as President – Business Development, Strategy and R&D

Cipla reports Q4 FY 23 consolidated PAT at Rs. 525.65 Cr

Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023

Briefs: IOL Chemicals and Cipla

Government of India has granted a patent for invention entitled "An improved safe process for the preparation of Sartan drugs of Formula I".

Cipla receives 6 observations from USFDA for Goa facility

There are no data integrity (DI) observations.

Five manufacturers get license to produce Black Fungus drug

NATCO Pharmaceuticals, Hyderabad; Alembic Pharmaceuticals, Vadodara; Gufic Biosciences Ltd., Gujarat; Emcure Pharmaceuticals, Pune; and Lyka, Gujarat are new manufacturers